CPRX · Insider Trading
Catalyst Pharmaceutical Inc.
Every open-market purchase and sale reported by CPRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | Molly Harper | Director | D | −3,694 | −$116.36K |
| 2026-07-17 | Richard J Daly | President and CEO | D | −271,266 | −$8.54M |
| 2026-07-17 | William T. Andrews | Chief Medical Officer | D | −2,309 | −$72.73K |
| 2026-07-17 | Donald A Denkhaus | Director | D | −498,773 | −$15.71M |
| 2026-07-17 | Steve Miller | Chief Op. & Scientific Officer | D | −1,093,803 | −$34.45M |
| 2026-07-17 | Gregg Russo | Chief HR Officer | D | −476 | −$14.99K |
| 2026-07-17 | David S Tierney | Director | D | −383,314 | −$12.07M |
| 2026-07-17 | Preethi Sundaram | Chief Strategy Officer | D | −54,804 | −$1.73M |
| 2026-07-17 | Jeffrey Del Carmen | Chief Commercial Officer | D | −14,337 | −$451.62K |
| 2026-07-17 | Michael Wayne Kalb | Chief Financial Officer | D | −13,665 | −$430.45K |
| 2026-07-17 | Tamar Thompson | Director | D | −3,773 | −$118.85K |
| 2026-07-17 | Daniel J. Curran | Director | D | −63,583 deriv. | — |
| 2026-07-17 | Patrick J McEnany | Director | D | −4,171,559 | −$131.40M |
| 2026-07-17 | Brian Elsbernd | Chief Legal Officer | D | −242,501 | −$7.64M |
| 2026-06-05 | William T. Andrews | Chief Medical Officer | MIXED | +2,309 | — |
| 2026-02-19 | Gregg Russo | Chief HR Officer | MIXED | +476 | — |
| 2026-01-06 | Richard J Daly | President and CEO | MIXED | +31,528 | — |
| 2026-01-06 | Michael Wayne Kalb | Executive Vice President & CFO | MIXED | +5,059 | — |
| 2025-12-30 | Steve Miller | Chief Op. & Scientific Officer | M | +14,000 | — |
| 2025-12-30 | Patrick J McEnany | Director | MIXED | +19,548 | — |
| 2025-12-30 | Donald A Denkhaus | Director | M | +1,334 | — |
| 2025-12-30 | Molly Harper | Director | M | +1,334 | — |
| 2025-12-30 | David S Tierney | Director | M | +1,334 | — |
| 2025-12-30 | Preethi Sundaram | Chief Strategy Officer | MIXED | +4,298 | — |
| 2025-12-30 | Brian Elsbernd | Chief Compliance/Legal Officer | MIXED | +4,044 | — |
| 2025-12-30 | Richard J Daly | President and CEO | MIXED | +810 | — |
| 2025-12-30 | Jeffrey Del Carmen | Chief Commercial Officer | MIXED | +4,828 | — |
| 2025-12-16 | Molly Harper | Director | MIXED | −6,746 | −$506.32K |
| 2025-12-10 | Steve Miller | Chief Op. & Scientific Officer | M | +11,873 | — |
| 2025-12-10 | David S Tierney | Director | M | +1,413 | — |
| 2025-12-10 | Tamar Thompson | Director | M | +1,413 | — |
| 2025-12-10 | Brian Elsbernd | Chief Compliance/Legal Officer | MIXED | +4,287 | — |
| 2025-12-10 | Donald A Denkhaus | Director | M | +1,413 | — |
| 2025-12-10 | Molly Harper | Director | M | +1,413 | — |
| 2025-12-10 | Preethi Sundaram | Chief Strategy Officer | MIXED | +5,186 | — |
| 2025-12-10 | Jeffrey Del Carmen | Chief Commercial Officer | MIXED | +5,547 | — |
| 2025-12-10 | Patrick J McEnany | Director | M | +3,534 | — |
| 2025-12-03 | Patrick J McEnany | Director | G | −135,000 | — |
| 2025-11-28 | Jeffrey Del Carmen | Chief Commercial Officer | MIXED | — | −$210.01K |
| 2025-11-24 | William T. Andrews | Chief Medical Officer | A | +128,428 deriv. | — |
| 2025-11-24 | Daniel J. Curran | Director | A | +23,583 deriv. | — |
| 2025-11-24 | Molly Harper | Director | M | +947 | — |
| 2025-11-24 | Michael Wayne Kalb | Executive Vice President & CFO | MIXED | +4,409 | — |
| 2025-11-24 | Gregg Russo | Chief HR Officer | A | +26,728 deriv. | — |
| 2025-11-24 | David S Tierney | Director | M | +947 | — |
| 2025-11-24 | Brian Elsbernd | Chief Compliance/Legal Officer | MIXED | +3,131 | — |
| 2025-11-24 | Tamar Thompson | Director | M | +947 | — |
| 2025-11-24 | Preethi Sundaram | Chief Strategy Officer | MIXED | +4,239 | — |
| 2025-11-24 | Steve Miller | Chief Op. & Scientific Officer | M | +8,267 | — |
| 2025-11-24 | Donald A Denkhaus | Director | M | +947 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Charles B O'Keeffe | Director | 732,470 | $23.07M |
| Patrick J McEnany | Director | 145,922 | $4.60M |
| Gary Ingenito | Chief Med. & Reg. Officer | 68,873 | $2.17M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CPRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.